BACKGROUND: Etomidate is a rapidly acting sedative-hypnotic that provides hemodynamic stability. It causes prolonged suppression of adrenocortical steroid synthesis; therefore, its clinical utility and safety are limited. The authors describe the results of studies to define the pharmacology of (R)-3-methoxy-3-oxopropyl1-(1-phenylethyl)-1H-imidazole-5-carboxylate (MOC-etomidate), the first etomidate analogue designed to be susceptible to ultra-rapid metabolism. METHODS: The gamma-aminobutyric acid type A receptor activities of MOC-etomidate and etomidate were compared by using electrophysiological techniques in human alpha1beta2gamma2l receptors. MOC-etomidate's hypnotic concentration was determined in tadpoles by using a loss of righting reflex assay. Its in vitro metabolic half-life was measured in human liver S9 fraction, and the resulting metabolite was provisionally identified by using high-performance liquid chromatography/mass spectrometry techniques. The hypnotic and hemodynamic actions of MOC-etomidate, etomidate, and propofol were defined in rats. The abilities of MOC-etomidate and etomidate to inhibit corticosterone production were assessed in rats. RESULTS: MOC-etomidate potently enhanced gamma-aminobutyric acid type A receptor function and produced loss of righting reflex in tadpoles. Metabolism in human liver S9 fraction was first-order, with an in vitro half-life of 4.4 min versus more than 40 min for etomidate. MOC-etomidate's only detectable metabolite was a carboxylic acid. In rats, MOC-etomidate produced rapid loss of righting reflex that was extremely brief and caused minimal hemodynamic changes. Unlike etomidate, MOC-etomidate produced no adrenocortical suppression 30 min after administration. CONCLUSIONS: MOC-etomidate is an etomidate analogue that retains etomidate's important favorable pharmacological properties. However, it is rapidly metabolized, ultra-short-acting, and does not produce prolonged adrenocortical suppression after bolus administration.
BACKGROUND:Etomidate is a rapidly acting sedative-hypnotic that provides hemodynamic stability. It causes prolonged suppression of adrenocortical steroid synthesis; therefore, its clinical utility and safety are limited. The authors describe the results of studies to define the pharmacology of (R)-3-methoxy-3-oxopropyl1-(1-phenylethyl)-1H-imidazole-5-carboxylate (MOC-etomidate), the first etomidate analogue designed to be susceptible to ultra-rapid metabolism. METHODS: The gamma-aminobutyric acid type A receptor activities of MOC-etomidate and etomidate were compared by using electrophysiological techniques in humanalpha1beta2gamma2l receptors. MOC-etomidate's hypnotic concentration was determined in tadpoles by using a loss of righting reflex assay. Its in vitro metabolic half-life was measured in human liver S9 fraction, and the resulting metabolite was provisionally identified by using high-performance liquid chromatography/mass spectrometry techniques. The hypnotic and hemodynamic actions of MOC-etomidate, etomidate, and propofol were defined in rats. The abilities of MOC-etomidate and etomidate to inhibit corticosterone production were assessed in rats. RESULTS:MOC-etomidate potently enhanced gamma-aminobutyric acid type A receptor function and produced loss of righting reflex in tadpoles. Metabolism in human liver S9 fraction was first-order, with an in vitro half-life of 4.4 min versus more than 40 min for etomidate. MOC-etomidate's only detectable metabolite was a carboxylic acid. In rats, MOC-etomidate produced rapid loss of righting reflex that was extremely brief and caused minimal hemodynamic changes. Unlike etomidate, MOC-etomidate produced no adrenocortical suppression 30 min after administration. CONCLUSIONS:MOC-etomidate is an etomidate analogue that retains etomidate's important favorable pharmacological properties. However, it is rapidly metabolized, ultra-short-acting, and does not produce prolonged adrenocortical suppression after bolus administration.
Authors: S Shaukat Husain; Selvanayagam Nirthanan; Dirk Ruesch; Ken Solt; Qi Cheng; Guo-Dong Li; Enrique Arevalo; Richard W Olsen; Douglas E Raines; Stuart A Forman; Jonathan B Cohen; Keith W Miller Journal: J Med Chem Date: 2006-08-10 Impact factor: 7.446
Authors: Diane Lipiner-Friedman; Charles L Sprung; Pierre François Laterre; Yoram Weiss; Sergey V Goodman; Michael Vogeser; Josef Briegel; Didier Keh; Mervyn Singer; Rui Moreno; Eric Bellissant; Djillali Annane Journal: Crit Care Med Date: 2007-04 Impact factor: 7.598
Authors: Bryan A Cotton; Oscar D Guillamondegui; Sloan B Fleming; Robert O Carpenter; Shivani H Patel; John A Morris; Patrick G Arbogast Journal: Arch Surg Date: 2008-01
Authors: Ilse M Zolle; Michael L Berger; Friedrich Hammerschmidt; Stefanie Hahner; Andreas Schirbel; Biljana Peric-Simov Journal: J Med Chem Date: 2008-03-19 Impact factor: 7.446
Authors: Charles L Sprung; Djillali Annane; Didier Keh; Rui Moreno; Mervyn Singer; Klaus Freivogel; Yoram G Weiss; Julie Benbenishty; Armin Kalenka; Helmuth Forst; Pierre-Francois Laterre; Konrad Reinhart; Brian H Cuthbertson; Didier Payen; Josef Briegel Journal: N Engl J Med Date: 2008-01-10 Impact factor: 91.245
Authors: Marieke den Brinker; Anita C S Hokken-Koelega; Jan A Hazelzet; Frank H de Jong; Wim C J Hop; Koen F M Joosten Journal: Intensive Care Med Date: 2007-08-21 Impact factor: 17.440
Authors: Luc Roumen; Marijn P A Sanders; Koen Pieterse; Peter A J Hilbers; Ralf Plate; Erica Custers; Marcel de Gooyer; Jos F M Smits; Ilona Beugels; Judith Emmen; Harry C J Ottenheijm; Dirk Leysen; J J R Hermans Journal: J Comput Aided Mol Des Date: 2007-07-24 Impact factor: 3.686
Authors: Ervin Pejo; Peter Santer; Lei Wang; Philip Dershwitz; S Shaukat Husain; Douglas E Raines Journal: Anesthesiology Date: 2016-03 Impact factor: 7.892
Authors: Joseph F Cotten; Stuart A Forman; Joydev K Laha; Gregory D Cuny; S Shaukat Husain; Keith W Miller; Hieu H Nguyen; Elizabeth W Kelly; Deirdre Stewart; Aiping Liu; Douglas E Raines Journal: Anesthesiology Date: 2010-03 Impact factor: 7.892
Authors: Talmage D Egan; Shinju Obara; Thomas E Jenkins; Sarah S Jaw-Tsai; Shanti Amagasu; Daniel R Cook; Scott C Steffensen; David T Beattie Journal: Anesthesiology Date: 2012-06 Impact factor: 7.892